Ichinosuke Hyodo

4PUBLICATIONS
50CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama

|Mar 25, 2025
A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).

Nozomu Machida, Takehiro Okumura, Narikazu Boku

|Oct 25, 2024
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.

Mika Okazawa-Sakai, Shunsuke A Sakai, Ichinosuke Hyodo

Pageof 1

Frequent Collaborators

2 joint publications

Mika Okazawa-Sakai

2 joint publications

Kimihiko Ito

2 joint publications

Kei Ihira

2 joint publications

Takao Fujisawa